Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2016-11-22 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于以募集资金置换预先投入募投项目的自筹资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the use of raised funds to replace self-raised funds previously invested in projects. It includes details about the fundraising, approvals by the board and supervisory committee, independent director opinions, and verification by an accounting firm. The document is relatively short (3044 characters) and primarily serves as a formal announcement of the fund replacement transaction rather than a full financial report or audit report. It does not contain comprehensive financial statements or detailed financial analysis. Therefore, it fits best as a Capital/Financing Update (CAP) since it relates to the company's fundraising and capital usage activities.
2016-11-22 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement by the company Beida Pharmaceutical Co., Ltd. regarding abnormal stock price fluctuations over two trading days. It includes detailed explanations and risk factors related to the stock price movements, confirms no undisclosed material information, and reminds investors of market risks. The document does not contain financial statements or detailed financial performance data, nor is it a report or transcript. It is a regulatory announcement about stock trading behavior and company disclosures, fitting the category of a Regulatory Filing (RNS). The document length is 4002 characters, which is relatively short and consistent with an announcement rather than a full report.
2016-11-17 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from a publicly listed company (贝达药业股份有限公司) regarding abnormal stock price fluctuations over a specific period. It includes detailed explanations and risk disclosures related to the stock price movements, regulatory compliance, and business risks. The document does not contain financial statements or detailed financial results but focuses on stock trading behavior and related company disclosures. It is not an annual or quarterly report, earnings release, or management discussion. It is a regulatory announcement about stock price abnormality and related risk factors, fitting the category of a Regulatory Filing (RNS). The document length is under 5,000 characters, and it is a standalone announcement rather than a report or presentation.
2016-11-14 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by the company regarding abnormal stock price fluctuations over two trading days. It includes detailed explanations and risk factors related to the company's business and stock price movements. The document does not contain financial statements or quarterly/yearly financial results, nor is it a transcript or presentation. It is a regulatory announcement addressing stock trading irregularities and related risk disclosures, typical of a regulatory filing. The document length is 4264 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS).
2016-11-09 Chinese
首次公开发行股票并在创业板上市上市公告书之补充说明公告
Capital/Financing Update Classification · 95% confidence The document is a supplementary announcement related to the company's initial public offering (IPO) and listing on the Growth Enterprise Market (创业板). It references a previously disclosed listing announcement document and provides additional financial tables for comparison. The document is short (566 characters) and serves as an update or supplement to an earlier filing rather than a full financial report or prospectus. It is an announcement related to capital market activities, specifically the IPO and listing process, but does not contain detailed financial statements or comprehensive report content itself. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes such as IPOs and listings.
2016-11-04 Chinese
首次公开发行股票并在创业板上市上市公告书（更新后）
Regulatory Filings
2016-11-04 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.